Preview

Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations

Satisfactory Essays
Open Document
Open Document
9655 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations
Toxicologic Pathology http://tpx.sagepub.com Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations
Brian G. Short Toxicol Pathol 2008; 36; 49 DOI: 10.1177/0192623307310955 The online version of this article can be found at: http://tpx.sagepub.com/cgi/content/abstract/36/1/49

Published by: http://www.sagepublications.com On behalf of:

Society of Toxicologic Pathology

Additional services and information for Toxicologic Pathology can be found at: Email Alerts: http://tpx.sagepub.com/cgi/alerts Subscriptions: http://tpx.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav

Downloaded from http://tpx.sagepub.com at University of Aston on February 10, 2010

Toxicologic Pathology, 36:49-62, 2008 Copyright © 2008 by Society of Toxicologic Pathology ISSN: 0192-6233 print / 1533-1601 online DOI: 10.1177/0192623307310955

Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations
BRIAN G. SHORT From Allergan, Inc., Irvine, California, USA.
ABSTRACT Development of new drug candidates and novel delivery techniques for treatment of ocular diseases has recently accelerated. Treatment of anteriorsegment diseases has witnessed advances in prodrug formulations and permeability enhancers. Intravitreal, subconjunctival, and periocular routes of administration and sustained-release formulations of nanoparticles and microparticles, as well as nonbiodegradable and biodegradable implants to deliver drugs to the posterior segment of the eye, are becoming popular therapeutic approaches. Without adequate regulatory guidance for ocular drugs, such routes of administration and novel formulations can pose unique challenges to those involved in designing nonclinical programs, including considering clinical and nonclinical factors and choosing species, strains, and ocular toxicity parameters. Toxicologic



References: Aronin, N. (2006). Target selectivity in mRNA silencing. Gene Ther 13, 509-16. Avalos, J., Jacobs, A., and Wilkin, J. K. (1997). Toxicity testing for ocular drug products. In Advances in Ocular Toxicology (K. Green et al., eds., pp. 261-8). Plenum, New York. Bourges, J. L., Bloquel, C., Thomas, A., Froussart, F., Bochot, A., Azan F., Gurny, R., BenEzra, D., and Behar-Cohen, F. (2006) Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 58, 1182-1202. Bourges, J. L., Gautier, S. E., Delie, F., Bejjani, R. A., Jeanny, J., Gurny, R., BenEzra, D., and Behar-Cohen, F. (2003). Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Opth Vis Sci 44, 3562-9. Clark, A. F, and Yorio, T. (2003). Ophthalmic drug discovery. Nature Rev 2, 448-59. Davis, J. L., Gilger, B. C., and Robinson, M. R. (2004). Novel approaches to ocular drug delivery. Curr Opin Mol Therap 6:195-205. Dureau, P., Bonnel, S., Menasche, M., Dufier, J. L., and Abitbol, M. (2001). Quantitative analysis of intravitreal injections in the rat. Curr Eye Res 22, 74-7. Eljarrat-Binstock, E., and Domb, A. J. (2006). Iontophoresis: a non-invasive ocular drug delivery. J Controlled Release 110, 479-89. Fattal, E., and Bochot, A. (2006). Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers, and siRNA. Adv Drug Deliv Rev 58, 1203-23. Ferrara, N., Damico, L., Shams, N., Lowman, H., and Kim, R. (2006). Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859-70. Friedrich, S. (2003). Mathematical modeling of drug distribution in the vitreous humor. In Ophthalmic Drug Delivery Systems (A. K. Mitra, ed., p. 195). Marcel Dekker, New York. Ghate, D., and Edelhauser, H. F. (2006). Ocular drug delivery. Expert Opin Drug Deliv 3, 275-87. Downloaded from http://tpx.sagepub.com at University of Aston on February 10, 2010 62 SHORT TOXICOLOGIC PATHOLOGY Herrero-Vanrell, R., and Refojo, M. F. (2001). Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv 52, 5-16. Heywood R., and Gopinath C. (1990). Morphological assessment of visual function. Tox Path 18, 204-217. Holland, J. M. (2005). Morphometric comparisons between cynomolgus monkeys and NZW rabbit eyes: implications for intravitreal implant studies. Data on file, Allergan, Inc, Irvine, CA. Hsu, J. (2007). Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 18, 235-9. Jaffe, G. L., Martin, D., Callanan, D., Pearson, A., Levy, B., Comsock, T., and Fluocinolone Acetonide Study Group. (2006). Fluocinolone acetonide: implant (retisert) for noninfectious posterior uveitis. Ophthalmology 113, 1020-7. Kim, H., Csaky, K. G., Gilger, B. C., Dunn, J. P., Lee, S. S., Tremblay, M., De Monasterio, F., Tansey, G., Yuan, P., Bungay, P. M., Lutz, R. J., and Robinson, M. R. (2005). Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci 46, 655-62. Kim, H., Csaky, K. G., Gravlin, L., Yuan, P., Lutz, R. J., Bungay, P. M., Tansey, G., De Monasterio, F., Potti, G. K., Grimes, G., and Robinson, M. R. (2006). Safety and pharmcokinetics of a preservative-free triamcinolone acetonide formulation for intraitreal administration. Retina 26, 523-30. Koch, F., and Kreiger, A. (1994). A light and electron microscopic study of the healing of pars plana incisions in the rhesus monkey. Graefe’s Arch Clin Exp Ophthalmol 232, 47-56. Kuppermann, B. D., Blumendranz, M. S., Haller, J. A., Williams, G. A., Weinberg, D. V., Chou, C., and Whitcup, S. M. (2007). Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125, 309-17. Latendresse, J. R., Warbrittion, A. R, Jonassen, H., and Creasy, D. M. (2002). Fixation of testes and eye using a modified Davison’s fluid: comparison with Bouin’s fluid and conventional Davidson’s fluid. Toxicol Pathol 30, 524-33. Leblanc, B., Jezequel, S., Davies, T., Hanton, G., and Taradach, C. (1998). Binding of drugs to eye melanin is not predictive of ocular toxicity. Reg Toxicol Pharmacol 28, 124-132. Leeds, J. M., Henry, S. P., Bistner, S., Scherrill, S., Williams, K., and Levin, A. A. (1998). Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos 26, 670-5. Leeds, J. M., Henry, S. P., Truong, L., Zutshi, A., Levin, A. A., and Kornbrust, D. (1997). Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab Dispos 25, 921-6. Lucentis (ranibizumab) Pharmacology Review (2006). Retrieved May 22, 2007, from Drugs@FDA Web site, http://www.fda.gov/cder/foi/nda/2006/ 125156s0000_Lucentis_PharmR.pdf Macugen (pegaptanib sodium) Pharmacology Review (2004). Retrieved May 22, 2007, from Drugs@FDA Web site, http://www.fda.gov/cder/foi/nda/2004/ 21-756_Macugen_pharmr.pdf McGee, D. H., Dembinska, O., and Gruebbel, M. (2005). Evaluation of triamcinolone acetonide following intravitreal injection in New Zealand white rabbits. Int J Toxicol 24, 419-25. Micera, A., Stampachiacchiere, B., Aronni, S., Serapiao dos Santos, M., and Lambiase, A. (2005). Toll-like receptors and the eye. Curr Opin Allergy Clin Immunol 5, 451-8. Morris, B., Imrie, F., Armbrecht, A., and Dhillon, B. (2007). Age-related macular degeneration and recent developments: new hope for old eyes? Postgrad Med J 83, 301-7. Morrison, V. L., Koh, H. J., Cheng, L., Bessho, K., Davison, M. C., and Freeman, W. R. (2006). Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 26, 339-44. Myles, M. E., Neumann, D. M., and Hill, J. M. (2005). Recent progress in ocular drug delivery for posterior segment disease: emphasis on transcleral iontophoresis. Adv Drug Deliv Rev 57, 2063-79. Ng, E. W., and Adamis, A. P. (2006). Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci 1082, 151-71. Okabe, J., Kimura, H., Kunou, N., Okabe, K., Kato, A., and Ogura, Y. (2003). Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Visual Sci 44, 740-4. Pearson, P. A., Jaffe, G. J., Martin, D. F., Cordahi, G. J., Grossniklaus, H., Schmeisser, E. T., and Ashton, P. (1996). Evaluation of a delivery system providing long-term release of cyclosporine. Arch Ophthalmol 114, 311-7. Perry, C. M., and Balfour, J. A. (1999). Fomiversen. Drugs 57, 375-80. Retisert (Fluocinolone Acetonide Intravitreal Implant) Pharmacology Review (2004). Retrieved May 22, 2007, from Drugs@FDA Web site, http://www .fda.gov/cder/foi/nda/2005/021737s000_PharmR.pdf Samuelson, D. A. (1999). Ophthalmic anatomy. In Veterinary Ophthalmology (3rd edition, K. Gelatt, ed., p. 111). Lippincott Williams & Wilkins, Philadelphia, PA. Sinha, D. P., Cartwright, M. E., and Johnson, R. C. (2006). Incidental mononuclear cell infiltrate in the uvea of cynomolgus monkeys. Toxicol Pathol 34, 148-51. Smith, T. J., Pearson, A., Blandford, D. L., Brown, J. D., Goins, K. A., Hollins, J. L., Schmeisser, E. T., Glavinos, P., Baldwin, L. B., and Ashton, P. (1992). Intravitreal sustained-release ganciclovir. Arch Ophthalmol 110, 255-8. Tao, W. (2006). Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 6, 717-26. Theng, J. T. S., Ei, T. S., Zhou, L., Lam, K. W., and Chee, S. P. (2003). Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest Ophthalmol Visual Sci 44, 4895-9. Vitravene (fomiversen) Pharmacology/Toxicology Review and Evaluation (1998). Retrieved May 22, 2007, from Drugs@FDA Web site http://www .fda.gov/cder/foi/nda/98/20961_Vitravene_pharmr.pdf Weir, A., Chambers, W., Chen, C., Chen, Z., Mukherjee, A., and Yang, J. (1999). Considerations for the nonclinical development of intravitreal drug products. Toxicologist 18, 323 (Abstract 1524). Whiteley, H. E., and Peiffer, R. L. (2002). The eye. In Handbook of Toxicologic Pathology (2nd ed., W. M. Haschek, C. G. Rousseaux, and M. A. Wallig, eds., pp. 539-84). Academic Press, San Diego, CA. Yasukawa, T., Ogura, Y., Kimura, H., Sakurai, E., and Tabata, Y. (2006). Drug delivery from ocular implants. Expert Opin Drug Deliv 3, 261-73. Younis, H. S., Picotti, J. R., Slim, R. M., Joniken, M., Burns-Nass, L. A., Heward, J., and Evering, W. (2007). Safety assessment of a VEGF receptor tyrosine kinase inhibitor, AG-023845, in cynomolgus monkeys following sub-Tenon ocular administration. Poster presentation, 8th Scientific Meeting of the Association for Ocular Pharmacology, February 9-11, San Diego, CA. Downloaded from http://tpx.sagepub.com at University of Aston on February 10, 2010

You May Also Find These Documents Helpful

  • Good Essays

    Case Study Hypomagnesemia

    • 651 Words
    • 3 Pages

    The patient has a new issue today of some irritation of his right eye. He does tell me this was a problem some time ago, as well and he did go to an urgent care. He was given a drop for that, at that point. He states he had leftover drops, and although they were expired, it does seem to be helping. The eye was quite red at one point.…

    • 651 Words
    • 3 Pages
    Good Essays
  • Satisfactory Essays

    Treatment is initiated with intravitreal antibiotic (amikacin 0.4mg in 0.1ml, or ceftrioxone 2mg in 0.1ml, and vancomycin1.0 mg in 0.1 ml) along with topical antibiotics. Direct and immediate pars plana vitrectomy is beneficial and recommended if visual acuity on presentation is light perception or worse. If fungal infection is suspected or culture is positive for fungus, intravitreal amphotericin B, 5 µgm in 0.1 ml is given…

    • 504 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Argus 2 Research Paper

    • 630 Words
    • 3 Pages

    Have you ever wonder if there is some type of device that can help heal the blind? Brian Mech, who is vice president of Second Sight Medical Products, had created the Argus II. This device was created for those who suffer from a genetic disease called Retinitis Pigmentosa or RP. The disease causes someone to lose vison because the retina isn’t functioning properly. The Argus II can actually send a signal to the implanted chip in the back of the eye’s retina and translates the directives into sight. The humanitarian device is able to change lives for those who struggle from the RP disease.…

    • 630 Words
    • 3 Pages
    Good Essays
  • Better Essays

    WGU Deathcap

    • 678 Words
    • 5 Pages

    Citations: 1) Lee, MD, D., Bentley, MD, S., & Bania, MD, T. (2012, December 6). Amatoxin…

    • 678 Words
    • 5 Pages
    Better Essays
  • Good Essays

    “The devices have yet to be tested in live animals or human patients, but the implants are exciting researchers because they might restore more vision than other retinal prosthetics being worked on”…

    • 606 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Fixed Dosal

    • 638 Words
    • 3 Pages

    Fixed Dosing (FD), Pro Re Nata (PRN) and Treat-and-Extend (TAE) Regimen of AFLIBERCEPT in Treatment of Polypoidal Choroidal Vasculopathy (PCV): a Systematic Review and Meta-analysis…

    • 638 Words
    • 3 Pages
    Good Essays
  • Good Essays

    3. Before one drop of 1% tropicamide was instilled into the pouch of subject A’s left eye, subject A was required to carry out the experiment for 15 minutes without the influence of the drug to obtain four baseline readings. Each baseline reading was taken at the interval of 5 minutes. The baseline readings obtained from subject A remained constant at 2.0mm from 0 to 15 minutes which means that the pupil diameter of subject A’s left eye remained constant at 2.0mm from 0 to 15 minutes without the influence of 1% tropicamide. At 15 minutes, one drop of 1% tropicamide was instilled into the pouch if subject A’s left eye. From 15 to 35 minutes, the pupil diameter of subject A’s left eye increased steadily from 2.0mm to 4.5mm. After 35 minutes, the pupil diameter of subject A’s left eye reached a plateau and the pupil diameter remained constant at 5.5mm until 90th minute. As for the right eye of subject A, subject A was required to take four baseline readings for the 1st 15 minutes at the interval of 5 minutes before one drop of 0.9% saline was instilled into the pouch of subject A’s right eye. The baseline readings obtained by subject A remained constant at 2.5mm throughout the 1st 15 minutes. However, the pupil diameter of subject A’s right eye did not change after 15minutes and remained constant at 2.5mm throughout the experiment.…

    • 1012 Words
    • 5 Pages
    Good Essays
  • Powerful Essays

    PLEASE SCROLL DOWN FOR ARTICLE Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.…

    • 7190 Words
    • 29 Pages
    Powerful Essays
  • Good Essays

    Bringing a drug through all phases of research usually takes years, and isn’t even possible without the collaboration of patients, doctors and study site staff. Every medication available to patient has followed this long, rigorous path, closely monitored throughout by numerous levels of regulation.…

    • 192 Words
    • 1 Page
    Good Essays
  • Best Essays

    Covell, C.A., Graziano, J., Rich, D., & Tobin, K.A. (2007). New outlook for age-related macular degeneration. Nursing2007, 37(3), 22-24.…

    • 1844 Words
    • 8 Pages
    Best Essays
  • Powerful Essays

    Nursing

    • 12029 Words
    • 49 Pages

    Herfindal, E. and Gourley D. (2000). Textbook of Therapeutics: Drug and Disease Management. Seventh Edition. Philadelphia, PA: Lippincott Williams and Wilkins.…

    • 12029 Words
    • 49 Pages
    Powerful Essays
  • Powerful Essays

    MacLaren, R.E., Groppe, M., Barnard, A.R., Cottriall, C.L., Tolmachova, T., Seymour, L., Clark, K.R., During, M.J., Cremers, E.P.M., Black, G.C.M., Lotery, A.J., Downes, S.M., Webster, A.R., & Seabra, M.C. (2014). Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. The Lancet, pp. 1-9. Published online January 16, 2014 http://dx.doi.org/10.1016/S0140-6736(13)62117-0…

    • 2113 Words
    • 9 Pages
    Powerful Essays
  • Better Essays

    Glaucoma is stealing away the vision and way of life from Americans every day. This disease is causing the vision of many Americans to be lost, and many more may soon follow. This disease is difficult to detect and the damage done is irreversible; but what if there was a solution? I am proposing a stem cell treatment for glaucoma that could that could heal the effects caused by glaucoma. This stem cell treatment allows for a promising non controversial solution to glaucoma induced blindness that could be easily produced and supported by the general public.…

    • 1507 Words
    • 7 Pages
    Better Essays
  • Best Essays

    Cited: 1The American Society of Health-System Pharmacists, Inc. "Methylphenidate Transdermal." PubMed Health. U.S. National Library of Medicine, 18 Dec. -0001. Web. 25 Apr. 2012. <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000341/>.…

    • 2246 Words
    • 9 Pages
    Best Essays
  • Good Essays

    Vitrectomy Research Paper

    • 373 Words
    • 2 Pages

    The probability of successful MH closure decreased by 6% with each month of delay prior to surgery.106 In addition, specific to VMT without MH, it has been suggested that excessive traction upon the fovea and its deformation can lead to structural changes that may not recover completely, either anatomically or functionally, after vitreous release. In one study, 69 cases of VMT that had recently converted from VMA were observed over a 2-year period; eight developed epiretinal membrane (ERM), six of which underwent vitrectomy with symptoms of reduced VA and metamorphopsia, five underwent cataract surgery, two developed MH, and one developed lamellar MH, whereas one patient had surgery to remove a dropped nucleus.148 The evolving evidence therefore suggests that observing VMT may result in progression of vitreomacular interface diseases, such as ERM, which can negatively impact success rates of subsequent intervention, highlighting the importance of considering early intervention in this group of symptomatic patients. Even with modern approaches, PPV may be associated with retinal detachment (7%), chronic intraocular pressure elevation (6%), and cystoid macular oedema (5%).149 In the NOD study,…

    • 373 Words
    • 2 Pages
    Good Essays

Related Topics